We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

77 hedge funds and large institutions have $183M invested in Iovance Biotherapeutics in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 17 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

599% more call options, than puts

Call options by funds: $2.95M | Put options by funds: $422K

71% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less funds holding

Funds holding: 82 → 77 (-5)

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

33% less capital invested

Capital invested by funds: $271M → $183M (-$88.7M)

Holders
77
Holders Change
-5
Holders Change %
-6.1%
% of All Funds
2.05%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
29
Reduced
17
Closed
16
Calls
$2.95M
Puts
$422K
Net Calls
+$2.53M
Net Calls Change
-$3.64M

Top Buyers

1
Axa
Axa
France
+$4.35M
2
ACP
Acuta Capital Partners
California
+$3.2M
3
OAM
Oxford Asset Management
United Kingdom
+$1.79M
4
GTC
Ghost Tree Capital
New York
+$1.37M
5
QF
QVT Financial
New York
+$901K

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$4.11M
2
PAWC
P.A.W. Capital
Connecticut
-$1.54M
3
PA
Perceptive Advisors
New York
-$1.17M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$950K
5
ACA
Avoro Capital Advisors
New York
-$342K
Name Holding Trade Value Shares
Change 		Change in
Stake
NC
26
Nexthera Capital
New York
$774K – – –
TCIM
27
TIAA CREF Investment Management
New York
$747K – – –
LCM
28
Landscape Capital Management
New Jersey
$699K +$249K +45,452 +49%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$485K +$65.4K +11,958 +14%
Swiss National Bank
30
Swiss National Bank
Switzerland
$367K +$71.1K +13,000 +21%
BA
31
BlackRock Advisors
Delaware
$360K – – –
Morgan Stanley
32
Morgan Stanley
New York
$336K +$18.9K +3,455 +6%
TA
33
Teachers Advisors
New York
$334K – – –
Goldman Sachs
34
Goldman Sachs
New York
$259K +$163K +29,820 +140%
TMC
35
Trellus Management Company
Florida
$254K -$57.7K -10,539 -17%
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$229K +$3.15K +575 +1%
Citigroup
37
Citigroup
New York
$221K +$129K +23,557 +117%
CIBC Private Wealth Group
38
CIBC Private Wealth Group
Georgia
$218K – – –
CS
39
Credit Suisse
Switzerland
$215K -$6.52K -1,191 -3%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$209K – – –
ProShare Advisors
41
ProShare Advisors
Maryland
$207K -$23.9K -4,365 -10%
Millennium Management
42
Millennium Management
New York
$187K +$33.9K +6,197 +20%
MLICM
43
Metropolitan Life Insurance Company (MetLife)
New York
$183K – – –
EMG
44
Ellington Management Group
Connecticut
$176K +$189K +34,600 New
VEA
45
Virtus ETF Advisers
New York
$164K +$177K +32,352 New
NFA
46
Nationwide Fund Advisors
Ohio
$153K – – –
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$147K +$5.68K +1,038 +4%
TI
48
Trexquant Investment
Connecticut
$141K +$151K +27,660 New
UBS AM
49
UBS AM
Illinois
$138K +$2.52K +461 +2%
AIG
50
American International Group
New York
$134K – – –
1
2
3 4

IOVA Hedge Fund Activity: Q1 2016 in Review

77 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2016, worth a combined $183M — down 33% from $271M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of IOVA and 11 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 29 added.

The largest buyer was Axa, opening a new position worth an estimated $4.35M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.11M.

  • 77 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2016, down from 82 in Q4 2015.
  • Funds reported $183M of Iovance Biotherapeutics stock for Q1 2016, down 33% quarter-over-quarter.
  • 11 funds opened new Iovance Biotherapeutics positions in Q1 2016 and 16 closed out, a net change of -5 holders.
  • The largest Iovance Biotherapeutics buyer in Q1 2016 was Axa, an estimated $4.35M added.
  • The largest Iovance Biotherapeutics seller in Q1 2016 was Baker Bros. Advisors, an estimated $4.11M sold.

Based on aggregated 13F filings for Q1 2016.